Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EPHEDRINE SULFATE vs GIAPREZA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.
A synthetic form of human angiotensin II, a vasoconstrictor that increases blood pressure by binding to angiotensin II type 1 receptors (AT1) on vascular smooth muscle, causing vasoconstriction.
Treatment of hypotension during spinal anesthesia,Bronchodilation in asthma (less common),Nasal congestion (topical use),Off-label: Treatment of shock, myasthenia gravis (with neostigmine)
Increase blood pressure in adults with septic or other distributive shock
50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.
1 mg/kg/min IV continuous infusion, titrated to achieve target mean arterial pressure; maximum dose 10 mg/kg/min.
Terminal elimination half-life 3-6 hours in adults with normal renal function; prolonged in renal impairment or alkaline urine.
Terminal elimination half-life is approximately 1 hour (range 0.5–2 hours); clinical context: requires continuous intravenous infusion for sustained vasopressor effect.
Ephedrine is metabolized primarily by oxidative deamination via monoamine oxidase (MAO) and also by N-demethylation via CYP450 isoenzymes, though specific CYP enzymes are not well characterized. It has a half-life of 3–6 hours.
Metabolized by aminopeptidase A and angiotensin-converting enzyme (ACE) to smaller fragments, including angiotensin (1-8).
Renal excretion of unchanged drug (60-70%) and minor metabolites; small amount biliary; p H-dependent; acidic urine enhances elimination.
Primarily via proteolysis; renal excretion of unchanged drug is negligible (<1%). Fecal excretion is minimal.
~20-30% bound, primarily to albumin.
~70% bound to plasma proteins, primarily to albumin.
~2-3 L/kg; indicates extensive tissue distribution; crosses blood-brain barrier.
Approximately 0.5 L/kg; indicates distribution primarily within extracellular fluid and plasma volume.
Oral: ~85% (first-pass metabolism minimal); IM/SC: nearly 100%.
Intravenous: 100% (only route of administration; oral bioavailability is negligible due to peptide degradation).
GFR 10-50 m L/min: administer 75% of normal dose every 6 hours. GFR <10 m L/min: administer 50% of normal dose every 6 hours.
No dose adjustment required for renal impairment.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use or use with extreme caution, reduce dose by 75%.
No dose adjustment required for hepatic impairment.
Oral: 3 mg/kg/day divided every 4-6 hours. Parenteral: 0.2-0.3 mg/kg/dose intramuscularly or subcutaneously every 4-6 hours; intravenous: 0.05-0.2 mg/kg/dose every 5-10 minutes as needed.
Safety and efficacy not established; no FDA-approved pediatric dosing.
Initiate at lower doses (e.g., 25 mg orally every 4-6 hours) due to increased sensitivity and risk of CNS stimulation and cardiovascular effects; monitor blood pressure and heart rate closely.
No specific adjustment recommended; use with caution due to potential cardiovascular comorbidities.
None.
No FDA black box warning.
Cardiovascular effects: hypertension, tachycardia, arrhythmias,Central nervous system stimulation: anxiety, insomnia, tremor,Tachyphylaxis with repeated use,Exacerbation of narrow-angle glaucoma,Use in patients with cardiovascular disease, hyperthyroidism, diabetes, or prostatic hypertrophy requires caution
Thromboembolic events (venous and arterial) have been reported; monitor for signs of thrombosis.,Risk of adverse reactions from coadministration with ACE inhibitors (increased response) or angiotensin receptor blockers (increased response).,Concomitant use with vasopressors may require dose adjustment.,Not recommended for patients with high output states (e.g., cardiogenic shock) unless as a rescue therapy.
Hypersensitivity to ephedrine or other sympathomimetics,Severe hypertension or coronary artery disease,Concurrent use with MAO inhibitors (MAOIs),Narrow-angle glaucoma,Pheochromocytoma,Hypertrophic obstructive cardiomyopathy
No absolute contraindications identified.,Relative contraindications: patients with known hypersensitivity to any component; patients with a history of severe hypertension; patients with a known high risk of arterial or venous thrombosis.
Avoid excessive caffeine intake (coffee, tea, colas) as it may increase stimulant effects and risk of cardiovascular side effects. Limit or avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) due to risk of hypertensive crisis. No other significant food interactions.
No known food interactions. GIAPREZA is administered intravenously and does not interact with food.
Ephedrine sulfate crosses the placenta. Use in the first trimester is associated with a small increased risk of gastroschisis. In the second and third trimesters, it may cause fetal tachycardia and uterine artery vasoconstriction, potentially leading to reduced uteroplacental blood flow. Animal studies have shown embryotoxicity at high doses.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental outcomes were observed at doses up to 2.1 times the maximum recommended human dose based on AUC. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: limited data; second and third trimesters: theoretical risk of fetal hypotension and hypoperfusion due to maternal hypotension.
Ephedrine is excreted into breast milk in small amounts. The milk-to-plasma ratio is approximately 2.5. At therapeutic doses, it is unlikely to cause adverse effects in the infant, but irritability and disturbed sleep have been reported. Caution is advised.
No data on presence in human milk, effects on breastfed infant, or effects on milk production. Consider developmental and health benefits of breastfeeding along with mother's clinical need for angiotensin II and any potential adverse effects on breastfed infant from drug or underlying maternal condition. M/P ratio not available.
Pregnancy does not significantly alter ephedrine pharmacokinetics. However, due to increased plasma volume and renal blood flow, the volume of distribution may be slightly increased. No routine dose adjustment is required, but careful titration is recommended due to altered vascular reactivity.
No specific dose adjustments recommended for pregnancy. Dose titration based on blood pressure response as in non-pregnant adults. Limited data on pharmacokinetic changes in pregnancy; consider potential increased volume of distribution and altered clearance, but no established dose modification.
Ephedrine sulfate is a direct and indirect sympathomimetic used primarily for hypotension during spinal/epidural anesthesia. It crosses the placenta and may cause fetal tachycardia. Avoid in patients with narrow-angle glaucoma, hyperthyroidism, or pheochromocytoma. Tachyphylaxis can develop with repeated doses. Use with caution in patients with cardiovascular disease, hypertension, or diabetes. Monitor blood pressure and heart rate closely.
GIAPREZA (angiotensin II) is indicated for the treatment of refractory hypotension in adults with distributive shock who have failed adequate volume resuscitation and other vasopressors. Do not administer with angiotensin-converting enzyme (ACE) inhibitors due to risk of excessive hypotension. Monitor blood pressure continuously during administration. Prepare using strict aseptic technique; discard unused portion. Dosage is based on the patient's baseline mean arterial pressure (MAP) and response. Use with caution in patients with severe hypertension or conditions that may be exacerbated by vasoconstriction.
Do not take this medication without your doctor's approval if you have high blood pressure, heart disease, or thyroid problems.,Avoid using other stimulants or decongestants while on this medication.,Report any chest pain, irregular heartbeat, or shortness of breath to your healthcare provider immediately.,This medication may cause dizziness or nervousness; avoid driving or operating heavy machinery until you know how it affects you.,If you are pregnant, planning to become pregnant, or breastfeeding, consult your doctor before using ephedrine.
This medication is used to increase your blood pressure if it is dangerously low and not responding to other treatments.,Your blood pressure will be monitored continuously during the infusion.,Inform your healthcare provider if you have a history of high blood pressure, heart disease, or any allergies.,Do not stop or change the dose without consulting your doctor.,Report any symptoms such as chest pain, shortness of breath, or headache immediately.
"Sevoflurane, a volatile halogenated anesthetic, sensitizes the myocardium to the arrhythmogenic effects of catecholamines such as ephedrine. This synergistic action can precipitate ventricular arrhythmias, including premature ventricular contractions, bigeminy, or, rarely, ventricular tachycardia, particularly in patients with underlying cardiac disease or electrolyte imbalances. Clinically, this interaction may manifest as intraoperative arrhythmias, hemodynamic instability, or increased perioperative cardiac risk."
"The combined use of ephedrine, a direct and indirect sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors, with nylidrin, a beta-adrenergic agonist that primarily targets beta-2 receptors to induce peripheral vasodilation, can lead to additive beta-adrenergic stimulation. This synergy increases the risk of cardiovascular adverse effects, including tachycardia, hypertension, myocardial ischemia, and arrhythmias, particularly in patients with pre-existing cardiovascular disease."
"Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), increases systemic norepinephrine levels by inhibiting its reuptake, leading to enhanced sympathetic tone. Ephedrine directly stimulates alpha- and beta-adrenergic receptors and also promotes norepinephrine release from presynaptic terminals. The concurrent elevation of norepinephrine from both mechanisms can synergistically increase heart rate and blood pressure, potentially resulting in severe tachycardia, hypertension, and elevated risk of arrhythmias or myocardial ischemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EPHEDRINE SULFATE vs GIAPREZA, answered by our medical review team.
EPHEDRINE SULFATE is a Vasopressor that works by Ephedrine sulfate is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors and indirectly stimulates norepinephrine release from sympathetic neurons, leading to vasoconstriction, bronchodilation, and increased heart rate and contractility.. GIAPREZA is a Vasopressor that works by A synthetic form of human angiotensin II, a vasoconstrictor that increases blood pressure by binding to angiotensin II type 1 receptors (AT1) on vascular smooth muscle, causing vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EPHEDRINE SULFATE and GIAPREZA depend on the specific clinical indication. These are both Vasopressor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EPHEDRINE SULFATE is: 50 mg orally every 3-4 hours as needed; 25-50 mg intramuscularly or subcutaneously every 3-4 hours; 5-25 mg intravenously slowly every 5-10 minutes as needed, not to exceed 150 mg in 24 hours.. The standard adult dose of GIAPREZA is: 1 mg/kg/min IV continuous infusion, titrated to achieve target mean arterial pressure; maximum dose 10 mg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EPHEDRINE SULFATE and GIAPREZA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EPHEDRINE SULFATE is classified as Category C. Ephedrine sulfate crosses the placenta. Use in the first trimester is associated with a small increased risk of gastroschisis. In the second and third trimesters, it may cause feta. GIAPREZA is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental outcomes were observed at doses up to 2.1 times the maximum reco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.